Long Term Follow up in Patients Who Underwent Boron Neutron Capture Therapy

2001 ◽  
pp. 141-144
Author(s):  
Yoshinobu Nakagawa ◽  
Pooh Kyonghon ◽  
Katsuji Kitamura ◽  
Teruyoshi Kageji ◽  
Takashi Minobe
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture ◽  
Long Term Follow Up

Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages

2005 ◽  
Vol 103 (6) ◽  
pp. 1000-1009 ◽  
Author(s):  
Shin-Ichi Miyatake ◽  
Shinji Kawabata ◽  
Yoshinaga Kajimoto ◽  
Atsushi Aoki ◽  
Kunio Yokoyama ◽  
...  
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Tumor Volume ◽  
Malignant Gliomas ◽  
Neutron Capture Therapy ◽  
Boron Compounds ◽  
Content Type ◽  
Boron Neutron Capture ◽  
Fine Print

Object. To improve the effectiveness of boron neutron capture therapy (BNCT) for malignant gliomas, the authors used epithermal rather than thermal neutrons for deep penetration and two boron compounds—sodium borocaptate (BSH) and boronophenylalanine (BPA)—with different accumulation mechanisms to increase the boron level in tumors while compensating for each other's faults. Methods. Thirteen patients, 10 of whom harbored a glioblastoma multiforme (GBM), one a gliosarcoma, one an anaplastic astrocytoma, and one an anaplastic oligoastrocytoma, were treated using this modified BNCT between January 2002 and December 2003. Postoperatively, neuroimaging revealed that only one patient with a GBM had no lesion enhancement postoperatively. The patients underwent 18F-BPA positron emission tomography, if available, to assess the accumulation and distribution of BPA before neutron radiotherapy. The neutron fluence rate was estimated using the Simulation Environments for Radiotherapy Applications dose-planning system before irradiation. The patients' volume assessments were performed using magnetic resonance (MR) imaging or computerized tomography (CT) scanning. Improvements in the disease as seen on neuroimages were assessed between 2 and 7 days after irradiation to determine the initial effects of BNCT; its maximal effects were also analyzed on serial neuroimages. The mean tumor volume before BNCT was 42.3 cm3. Regardless of the pre-BNCT tumor volume, in every patient harboring an assessable lesion, improvements on MR or CT images were recognized both at the initial assessment (range of volume reduction rate 17.4–71%, mean rate 46.4%) and at follow-up assessments (range of volume reduction rates 30.3–87.6%, mean rate 58.5%). More than 50% of the contrast-enhanced lesions disappeared in eight of the 12 patients during the follow-up period. Conclusions. This modified BNCT produced a good improvement in malignant gliomas, as seen on neuroimages.

Boron Neutron Capture Therapy: Long-Term Effects on the Skin and Spinal Cord of the Rat

1993 ◽  
Vol 135 (3) ◽  
pp. 380 ◽  
Author(s):  
G. M. Morris ◽  
G. Constantine ◽  
G. Ross ◽  
T. K. Yeung ◽  
J. W. Hopewell
Keyword(s):  
Spinal Cord ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Long Term Effects ◽  
Boron Neutron Capture

Boron Neutron Capture Therapy for Malignant Tumors Related To Meningiomas

Neurosurgery ◽  
2007 ◽  
Vol 61 (1) ◽  
pp. 82-91 ◽  
Author(s):  
Shin-Ichi Miyatake ◽  
Yoji Tamura ◽  
Shinji Kawabata ◽  
Kyoko Iida ◽  
Toshihiko Kuroiwa ◽  
...  
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Clinical Symptoms ◽  
Malignant Tumors ◽  
Complete Response ◽  
Cervical Lymph Node Metastasis ◽  
Atypical Meningioma ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

Abstract OBJECTIVE Malignant meningiomas, similar to glioblastomas, are difficult tumors to control. We tried to control malignant tumors related to meningiomas by boron neutron capture therapy (BNCT). METHODS Since June 2005, we applied BNCT with 13 rounds of neutron irradiation to seven cases of malignant tumors related to meningiomas. Three were anaplastic meningiomas, two were papillary meningiomas, one was an atypical meningioma, and one was a sarcoma transformed from a meningioma with cervical lymph node metastasis. All patients had previously undergone repetitive surgeries and radiotherapy. Follow-up images were available for six patients with an observation period between 7 and 13 months. We applied 18F-boronophenylalanine (BPA)-positron emission tomography (PET) before BNCT in six of the seven patients. One patient underwent methionine-PET instead of 18F-BPA-PET. RESULTS Five of the six patients who underwent BPA-PET analysis showed good BPA uptake, with a greater than 2.7 tumor-to-healthy brain ratio. The atypical meningioma case showed a tumor-to-healthy brain ratio of 2.0. The original tumor sizes were between 13.6 and 109 ml. Two of the three anaplastic meningiomas showed a complete response, and all six patients available for follow-up imaging showed radiographic improvements. Clinical symptoms before BNCT, such as hemiparesis and facial pain, were improved after BNCT in all but one patient. In this patient, a huge atypical meningioma arose from the falcotentorial junction and extended to the bilateral occipital lobes and brainstem; visual problems worsened after repetitive BNCT, with an increase in peritumoral edema. CONCLUSION Malignant meningiomas seem to be good candidates for BNCT.

scholarly journals Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT)

2020 ◽  
Vol 61 (6) ◽  
pp. 945-951
Author(s):  
Junichi Hiratsuka ◽  
Nobuhiko Kamitani ◽  
Ryo Tanaka ◽  
Ryoji Tokiya ◽  
Eisaku Yoden ◽  
...  
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Cutaneous Melanoma ◽  
Neutron Capture ◽  
Early Stage ◽  
Regional Lymph Node ◽  
Skin Dose ◽  
Neutron Capture Therapy ◽  
Long Term Outcome ◽  
Boron Neutron Capture

ABSTRACT Our aim was to assess the long-term clinical outcome of boron neutron capture therapy (BNCT) using 10B-para-boronophenylalanine (BPA) as the boron delivery agent for cutaneous melanoma. Eight patients (eight lesions) were treated between October 2003 and April 2014. Their ages ranged from 48 to 86 years at the time of treatment. All of the targets were primary lesions and they were located on the sole or face. No patient had evidence of regional lymph node involvement, distant metastases or an active secondary cancer. The clinical stage was cT1-2N0M0 and performance scores were <2. BNCT was carried out at the Kyoto University Research Reactor (KUR). The patients were irradiated with an epithermal neutron beam between the curative tumor dose and the tolerable skin dose. Eight patients were evaluated and six showed a complete response (CR), while two patients had a partial response (PR). Of the two patients with a PR, one has remained a PR with brown spots persisting for 7.5 years following BNCT. The tumor in the other patient recurred after 6 years at the site of persisting brown macula. The overall control rate (CR + PR without recurrence) for the cohort was 88% (7/8). There have never been any adverse events >Grade 2 for the long follow-up period. Our results suggest that BNCT may be a promising treatment modality in the management of early stage cutaneous melanoma when wide local excision is not feasible.

Assessment of long-term risks of secondary cancer in paediatric patients with brain tumours after boron neutron capture therapy

2019 ◽  
Vol 39 (3) ◽  
pp. 838-853
Author(s):  
Xinxin Zhang ◽  
Changran Geng ◽  
Xiaobin Tang ◽  
Silva Bortolussi ◽  
Diyun Shu ◽  
...  
Keyword(s):  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Brain Tumours ◽  
Neutron Capture Therapy ◽  
Secondary Cancer ◽  
Boron Neutron Capture ◽  
Paediatric Patients
Sign in / Sign up

Export Citation Format

Share Document